Alveron Pharma
Healthcare & Life Sciences
Recent Finacing
Seed
Recent Raise
$5.3M
Alveron Pharma develops a drug, OKL-1111, to treat intracranial haemorrhage by reversing the effects of anticoagulants and platelet inhibitors.
Focus Areas
Pharmaceuticals
Intracranial Hemorrhage
Anticoagulant Reversal
Drug Development
Clinical Studies
Investors
